Xeljanz - IBD News Today
Xeljanz (tofacitinib) is a Janus kinase (JAK) inhibitor that has shown promise in Phase 3 clinical trials as a treatment for ulcerative colitis.
Source: ibdnewstoday.com
📰 Clinical Development Program News
Page 7 - Clinical Development Program News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Clinical Development Program. Real-time updates on events, politics, business and more.
Daiichi Sankyo: ENHERTU Approved in the EU as the First HER2 Directed Therapy for Patients with HER2 Low Metastatic Breast Cancer
Approval based on DESTINY-Breast04 results where Daiichi Sankyo and AstraZeneca's ENHERTU reduced the risk of disease progression or death by 50% and increased median overall survival by more than
United States Koji Ogiwara Daiichi Sankyo Daiichi Sankyo Europe Gmb Simone Jendsch Dow Arch Pathol Lab
Source: finanznachrichten.de
ENHERTU® Approved in the EU for Patients with Previously Treated HER2 Positive Advanced Gastric Cancer
L’AFP est une agence d’information globale, assurant une couverture rapide, complète et vérifiée des événements de l’actualité comme des thèmes qui façonnent notre quotidien. Avec un réseau de journalistes sans égal, déployé sur 151 pays, l'AFP est en outre un leader mondial de l’investigation nu...
Source: afp.com
Daiichi Sankyo: ENHERTU Achieved Statistically Significant Overall Survival Reducing the Risk of Death by 36% Versus Trastuzumab Emtansine (T-DM1) in Patients with HER2 Positive Metastatic Breast Cancer in DESTINY-Breast03
Daiichi Sankyo and AstraZeneca's ENHERTU also improved progression-free survival by 22 months versus T-DM1 in patients previously treated with HER2 directed therapy in the DESTINY-Breast03 phase
Source: finanznachrichten.de
Lilly receives U.S. FDA Fast Track designation for tirzepatide for the treatment of adults with obesity, or overweight with weight-related comorbidities
/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the...
Source: prnewswire.com
GRAIL, LLC: GRAIL Announces Final Results From the PATHFINDER Multi-Cancer Early Detection Screening Study at ESMO Congress 2022
Adding Multi-Cancer Early Detection (MCED) Screening to Standard of Care Screening More Than Doubled the Number of Cancers Detected 71% of Participants With MCED-Detected Cancers Had Cancer Types
Source: finanznachrichten.de
AstraZeneca (NASDAQ:AZN) – ENHERTU® Continues to Demonstrate Clinically Meaningful Tumor Response in Patients with HER2 Mutant Metastatic Non-Small Cell Lung Cancer - Press Release
DESTINY-Lung02 phase 2 trial shows clinically meaningful efficacy and favorable safety at 5.4 mg/kg dose versus 6.4 mg/kg dose of Daiichi Sankyo and A
United States Ken Takeshita Daiichi Sankyo Cristian Massacesi National Cancer Center Hospital Arch Pathol Lab
Source: wiredprnews.com
GRAIL, LLC: CORRECTING and REPLACING GRAIL Announces Final Results From the PATHFINDER Multi-Cancer Early Detection Screening Study at ESMO Congress 2022
Please replace the release with the following corrected version. A multimedia asset accompanying this release and paragraph seven have been removed. This press release features multimedia. View the
Source: finanznachrichten.de
GRAIL Announces Final Results From the PATHFINDER Multi-Cancer Early Detection Screening Study at ESMO Congress 2022
Press release content from Business Wire. The AP news staff was not involved in its creation.
Source: apnews.com
CORRECTING and REPLACING GRAIL Announces Final Results From the PATHFINDER Multi-Cancer Early Detection Screening Study at ESMO Congress 2022
Press release content from Business Wire. The AP news staff was not involved in its creation.
Source: apnews.com